Shopping Cart
Remove All
Your shopping cart is currently empty
PROTACHPK1 Degrader-5 is a potent, orally active HPK1 PROTAC degrader with a DC50 of 5.0 nM and a Dmax of at least 99%. It significantly inhibits HPK1 by degrading it, reducing SLP76 phosphorylation, and enhancing ERK pathway activation, which in turn stimulates the release of IL-2 and IFN-γ. This compound effectively counteracts immune suppression induced by PGE2, NECA, or TGF-β. Alone, PROTACHPK1 Degrader-5 is capable of suppressing tumor growth in MC38 syngeneic mouse models. It is used in research for immunotherapy applications in cancers such as colorectal cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PROTACHPK1 Degrader-5 is a potent, orally active HPK1 PROTAC degrader with a DC50 of 5.0 nM and a Dmax of at least 99%. It significantly inhibits HPK1 by degrading it, reducing SLP76 phosphorylation, and enhancing ERK pathway activation, which in turn stimulates the release of IL-2 and IFN-γ. This compound effectively counteracts immune suppression induced by PGE2, NECA, or TGF-β. Alone, PROTACHPK1 Degrader-5 is capable of suppressing tumor growth in MC38 syngeneic mouse models. It is used in research for immunotherapy applications in cancers such as colorectal cancer. |
| In vitro | PROTAC HPK1 Degrader-5 (Compound 10m) at 30 nM, after 24 hours, facilitates the degradation of HPK1 in Jurkat cells, relying on the ubiquitin-proteasome system (UPS), CRBN, HPK1, and CRBN. At a concentration of 10 nM, this compound significantly and dose-dependently inhibits phosphorylation of SLP76 in Jurkat cells and in PBMCs stimulated with anti-CD3/CD28 antibodies, while enhancing activation of extracellular signal-regulated kinase (ERK), which aligns with HPK1 degradation. |
| In vivo | PROTAC HPK1 Degrader-5 (Compound 10m), administered orally at doses of 0.5-3 mg/kg every other day for 14 days, significantly inhibits tumor growth in MC38 syngeneic mouse models. When combined with a PD-1 inhibitor, it achieves superior antitumor effects. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.